Sorrento Therapeutics Inc.

03/07/2021 | Press release | Distributed by Public on 03/07/2021 21:30

Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of[...]